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Abstract
Background: Insecticide-treated nets (ITNs) are an effective and cost-effective means of malaria
control. Scaling-up coverage of ITNs is challenging. It requires substantial resources and there are
a number of strategies to choose from. Information on the cost of different strategies is still scarce.
To guide the choice of a delivery strategy (or combination of strategies), reliable and standardized
cost information for the different options is required.
Methods:  The electronic online database PubMed was used for a systematic search of the
published English literature on costing and economic evaluations of ITN distribution programmes.
The keywords used were: net, bednet, insecticide, treated, ITN, cost, effectiveness, economic and
evaluation. Identified papers were analysed to determine and evaluate the costing methods used.
Methods were judged against existing standards of cost analysis to arrive at proposed standards for
undertaking and presenting cost analyses.
Results: Cost estimates were often not readily comparable or could not be adjusted to a different
context. This resulted from the wide range of methods applied and measures of output chosen.
Most common shortcomings were the omission of certain costs and failure to adjust financial costs
to generate economic costs. Generalisability was hampered by authors not reporting quantities and
prices of resources separately and not examining the sensitivity of their results to variations in
underlying assumptions.
Conclusion: The observed shortcomings have arisen despite the abundance of literature and
guidelines on costing of health care interventions. This paper provides ITN specific
recommendations in the hope that these will help to standardize future cost estimates.
Introduction
Insecticide-treated nets (ITNs) are an effective tool for the
prevention of morbidity and mortality caused by malaria
[1] and other vector-borne diseases [2]. Cost-effectiveness
of ITNs in the prevention of malaria has also been amply
demonstrated in a variety of settings [3-5]. The present
challenge is to scale-up and sustain coverage with ITNs
[6]. Many approaches to ITN delivery have evolved. These
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vary widely in scale, target populations and in the strategy
used to provide nets and insecticide to the end user.
Recent advances in the development of nets with long-
lasting insecticide impregnations (LLINs) simplify strate-
gies by reducing the need for re-treatment [7,8].
To choose a delivery strategy (or combination of strate-
gies), health planners and policy makers require reliable
and standardised information on the cost per unit cover-
age [9]. Standardized costs are also needed for use in com-
bination with effectiveness estimates to judge the
efficiency of ITN programmes and the scope for their
improvement. To generate data whereby alternative
approaches can be compared a common set of techniques
will need to be proposed and agreed upon [5,10]. The
present study aims at contributing towards this process by
reviewing the existing literature on costing and cost-effec-
tiveness of ITN distribution programmes, identifying
short-comings and suggesting ways to improve on quality
and comparability of costing methods.
Materials and methods
A systematic search of the published English literature on
costing and economic evaluations of ITN distribution
programmes was conducted by means of the electronic
online database PubMed (US National Library of Medi-
cine, Bethesda, USA). The keywords used were: net, bed-
net, insecticide, treated, ITN, cost, effectiveness, economic
and evaluation. These searches were supplemented by
iterative reviews of reference lists of relevant published
papers. Two consultancy reports were also included.
All papers that provided cost estimates for the delivery of
mosquito nets and/or insecticide treatment were consid-
ered relevant, even if they did not fully satisfy the criteria
of a costing study [11]. To fulfil the aim of the present
review of providing comprehensive guidance on how to
improve and standardise costing of ITN distribution pro-
grammes, it was considered important to use cost and
costing in their broader sense.
Studies were examined by means of a checklist adapted
from other publications [12-14]. A summary of the fol-
lowing information was prepared: delivery and financing
mechanism used, type of study (costing or cost-effective-
ness), country where the study was implemented, perspec-
tive from which the authors measured costs, costs
included, whether or not guidelines were used to assist in
the identification, measurement and/or valuation of
inputs, year of prices and results obtained. During this
process, all studies that had been referred to by the
authors as addressing cost-effectiveness were allocated to
this category, rather than attempting to reclassify them to
more precise categories such as those proposed elsewhere
[11].
Results
Twenty-six documents including two consultancy reports,
published between 1989 and 2005, were identified as
containing relevant cost estimates. Overall, 15 of the stud-
ies used an intermediate output (henceforth referred to as
cost studies) whereas 11 related cost to a health outcome
(cost-effectiveness studies) (Table 1).
Technical characteristics
Viewpoint taken
A study's viewpoint determines the costs to be included in
the analysis. Though the perspective was sometimes not
explicitly stated, it was possible to infer it for all the papers
after consideration of the costs included. The majority of
studies were conducted from the perspective of the service
provider (Table 1). The use of a societal viewpoint was
limited to five of the cost-effectiveness and one of the cost
studies. Less than half of the cost-effectiveness studies
included the societal viewpoint among the alternatives
investigated. One study examined only the patients' view-
point.
Types and clarity of cost measures
Financial costs of the service provider were included in all
but one study, which was costed from the patients' view-
point. Considerable variation was observed between stud-
ies in the items identified and measured. No general
template could be identified by which authors had
decided which inputs to include. Few studies detailed all
the inputs, their unit cost, quantities consumed and rea-
sons for inclusion/exclusion in the analysis. This observed
lack of consistency and often detail could not be attrib-
uted to authors not consulting the relevant health eco-
nomics literature. More than half of the studies referred to
papers on costing or to one of the leading texts in this
field. Most frequently quoted were Phillips et al [15],
Creese and Parker [16], the first and second editions of
Drummond et al. [17] and Gold et al. [18].
Insufficient attention was given to the cost of reaching
specific target groups; in the case of ITNs these are gener-
ally children below the age of five or pregnant women.
Two papers explicitly recognized this cost. Guyatt et al.
[19] calculated two costs, one for delivery of nets to all
users and a higher one for delivery to pregnant women
(i.e. accounting for the proportion of nets that had been
taken-up by other users). An intervention trial in northern
Ghana considered it necessary to distribute nets to all fam-
ily members to ensure that children were protected and
considered this in the cost estimate [20].
Studies varied greatly in the way in which financial costs
were adjusted to obtain economic costs (i.e. annualized
and discounted) and which other economic costs, such as
donated items and time of volunteers, were included.M
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Table 1: Summary of studies that provide cost estimates of the delivery of insecticide and/or nets
Category* Distribution Study** Country Perspective Cost included Guidelin
e used***
Year of 
price
Currenc
y
Cost**** Source
Financial Economic Per net 
delivered
Per 
treatment 
delivered
Per ITN 
delivered
Per 
treated 
net year
Per person 
protected
Public/
Public
Campaign 
(Door-to-door)
C Solomon Islands 
(Florida Islands)
Provider Nets, insecticide, transport, 
fuel, repairs, wages, 
equipment, materials, 
facilities
Time taken Yes 1988/89 SI$ 3.85 (= 
US$ 1.97)
341
Campaign 
(Door-to-door)
CC h i n a  ( N a p o  
County)
Provider Insecticide No 1990 – 92 Yuan 0.48F 35
Campaign 
(Door-to-door)
CE Northern Ghana 
(Kassena – 
Nankana district)
Provider Nets, insecticide, wages, 
transport, supplies & 
services
Adjusted financial 
costs plus time of 
volunteers
Yes 1993/94 US$ (and 
Cedis)
2.40 20
General health 
facilities
CE The Gambia Provider Nets, insecticide, etc. (taken 
from Picard et al. 1993)
Adjusted financial 
costs
No 1990 US$ 6.24 36
Campaign 
(Door-to-door)
C Tanzania Provider Nets, insecticide, wages, 
transport
Cost of nets was 
annualised (but not 
discounted)
No 1996 US$ 1.00F 0.46F 1.46F 37
Campaign 
(Distrib. point 
not specified; 
assumed 
central)
CE Thailand (Thai-
Myanmar 
Border)
Patients Direct medical costs, 
transportation, food
Time absent from 
work
Yes 1994/95 US$ 38
Campaign 
(Door-to-door)
C Pakistan (Afghan 
refugee camps)
Provider Net, insecticide, operational 
costs
Cost of net 
annualised (but not 
discounted)
No 1991 – 94 US$ 1.51 39
Campaign 
(Fixed-site)
CE South Africa 
(KwaZulu-Natal)
Provider Nets, insecticide, wages, 
equipment, transport, 
storage space
Adjusted financial 
cost plus donated 
insecticide
Yes 1999 US$ (and 
Rand)
3.82 40
Campaign 
(Distrib. point 
not specified; 
assumed to be 
central)
CE Thailand (Thai-
Myanmar border)
Provider Wages, material, capital cost Yes 1994 US$ 1.30F 41
Antenatal 
Clinics
C Kenya Provider Net and insecticide, 
transport
No 2001 US$ 3.81F 5.26F, 
L
19
Public/
Public
Campaign 
(Door-to-door)
C Columbia Provider Wages, per diems, 
insecticide, transport
Yes 2001 US$ 5.10F (near) 
12.40F (far)
42
Campaign 
(Fixed-site)
C Tropical Africa Provider Nets, wages, allowances, 
transport
Yes 2003 US$ 2.40F 22
Campaign 
(Fixed-site)
CE Kenya Society Insecticide, nets, wages, 
supplies, transport, buildings, 
equipment, furniture, water, 
time of users
Adjusted financial 
costs plus value of 
community labour
Yes 1996 US$ 1.90NC 
2.20N
1.4NC 1.6N 4
Measles 
vaccination 
sites
C Ghana Provider ITNs, training and 
supervision, transportation, 
community education
No 2002 US$ 3.74F 43
Public/
Mixed
Campaign – 
fixed site (Field 
trial using PHC 
workers & 
villagers)
CE The Gambia Society Insecticide, wages, transport, 
equipment, treatment, 
funeral expenses
Adjusted financial 
costs plus time of 
volunteers, carers, 
hours lost due to 
mourning
Yes 1990 US$ 5.65 44M
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Local clinics 
Mobile teams 
CHW
C Afghanistan Provider Nets, insecticide, 
monitoring, supervision, 
training, clinic overheads, 
wages, transport
Cost per net was 
adjusted (but not of 
other capital items)
Yes 1995 US$ 2.01 1.89 1.08 0.49 
1.87
45
Campaign 
(Door-to-door)
CE The Gambia 
(National 
Programme)
Society 
(Provider + 
Community)
Insecticide, wages, supplies, 
services, transport, 
equipment, awareness 
campaign, community capital 
costs incl. nets
Adjusted financial 
costs plus 
community time and 
water
Yes 1991 – 92 US$ (and 
Dalasis)
1.00N 3.30N 26
Campaign 
(Fixed site)
CV i e t n a m  ( H o a  
Binh Province)
Provider Insecticide, equipment, 
labour, nets and transport 
(purchased by community)
Adjusted financial 
costs
Yes 1996 US$ 0.58 – 
0.61P
0.32P 0.90 – 0.93 31
Mixed/
Mixed
Public and 
private sales 
agents
C Tanzania Project costs 
and users' 
contributions
No 1998 – 99 US$ 6.14 – 
6.87F
1.72 – 2.11F 46
Public and 
private sales 
agents
CE Tanzania Project 
implementation 
costs, user 
contributions, 
travel costs
Adjusted financial costs plus 
time of users, in-kind 
community contributions, 
donated inputs
Yes 2000 US$ (and 
Shillings)
8.30F 13.38 5
General health 
facilities & 
commercial 
outlets
CE Malawi Provider Capital and recurrent costs Adjusted capital 
costs (assumed life-
span as in Hanson et 
al. 2003)
Yes 1998 – 
2003
US$ 2.63 4.41 27
Private/
Mixed
Community 
(Community 
groups)
C, CE Kenya (Western 
highlands)
Provider & 
Society
Wages, nets, insecticide, 
cost-recovery included and 
excluded in analysis
Adjusted financial 
costs plus 
opportunity cost of 
MoH Government, 
community, and of 
using NGO truck
Yes 2000 US$ (and 
Shillings)
4.68 30.00O 47,48
Private/
Private
Community C Benin (Savalou 
region)
Provider Local mosquito net 
production, insecticide, 
transportation, wages
No 1993 US$ (and 
CFA)
10.50F(sales 
price incl. 
profit)
49
Community 
(Community 
groups)
C Kenya Provider Nets, netting material, 
insecticide, project running 
cost, monitoring, awareness 
campaign, training, transport
Some financial costs 
adjusted (but nets 
not included as 
capital items)
No 2002 US$ 15.80F 
14.40
9
Formal sector 
retail outlet
C The Gambia Provider Net (locally made), 
insecticide
Cost of net 
annualised but not 
discounted
No 1987 US$ 1.75 0.30 2.05 50
* Delivery Point/Financing of net & insecticide (Public = Free, Mixed = Partially Subsidised, Private = Full Cost and includes payment by households)
** C = Study providing cost estimate; CE = Study carried out to establish cost-effectiveness
*** Guidelines include reference by the authors to relevant documents for guidance on costing
**** Economic cost is provided unless otherwise indicated (economic costs are derived from financial costs by excluding VAT, annualising capital costs and annualising programme development 
costs over expected useful life of net)
C Community effect included; also called 'mass effect', see reference 51 and 52 for examples
F Financial cost, rather than economic cost
I Incremental cost over two year study period
L Cost including leakage to non-target group
N Net cost, i.e. total implementation cost minus resources saved
O Cost estimate including overheads to support the NGO facilitating the ITN programme
P Average cost per person protected, not per net; generally nets were single or double size
1 see reference 23 for price in US$
Table 1: Summary of studies that provide cost estimates of the delivery of insecticide and/or nets (Continued)Malaria Journal 2006, 5:37 http://www.malariajournal.com/content/5/1/37
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Eight studies only included financial costs. Some studies
quoted the cost net of any cost savings, and one study
included the community effect, i.e. the protection gained
by people without a mosquito net when sleeping near ITN
users. Comparison of cost estimates between studies that
had used the same output was therefore not always mean-
ingful.
Sources of cost data
A number of studies were undertaken alongside the early
efficacy trials for ITNs, which will have facilitated the col-
lection of cost data. However, the resulting cost estimates
may be an overestimate of the costs of a routine interven-
tion because efficacy trials require close monitoring and
supervision to provide reliable clinical results; in such cir-
cumstances effectiveness may also be overestimated com-
pared to routine conditions [21]. On the opposite end of
the spectrum, one study collected cost data for ITN distri-
bution alongside measles vaccination, but did not fully
account for the proportional use of campaign resources.
Some studies did not collect primary data on expenditure.
Instead, investigators either used results of other studies to
recalculate cost estimates under different assumptions or
a combination of results from other studies extrapolated
to a generalized scenario [see [22]].
Issues of time
An ITN programme generally lasts for more than one year
and the capital items purchased to implement it mostly
have a life expectancy in excess of one year. It is therefore
useful to express capital costs as an annual equivalent,
which requires judgements on the average life expectancy
of each type of item and choice of a discount rate. Capital
inputs that were annualised included mosquito nets, vehi-
cles and equipment. Assumptions on the life expectancy
and discount rate varied considerably between studies.
Mosquito nets were considered to last three to seven years,
the need to re-treat them was estimated at once or twice a
year and the number of people protected by each net
ranged from one to more than three. Discount rates
applied to capital items ranged from 3% to 10%.
Choice of output and outcome measure
Costs were generally quoted in US$ and in some cases also
in the equivalent local currency. Two studies provided
results only in local currency. Overall, five intermediate
output measures were encountered: i) Cost per net deliv-
ered, ii) Cost per insecticide treatment delivered, iii) Cost
per ITN delivered, iv) Cost per treated net year, and v)
Cost per person protected. More than half of the studies
provided only one of these; the preferred one being cost
per ITN delivered. Programmes that did not distribute pre-
treated nets could have distinguished the costs of deliver-
ing the net and insecticide, but often failed to report these
separately. Outputs were thus not easily comparable
between studies and the information provided was insuf-
ficient to calculate cost for a different output measure
from that provided by the authors.
Most of the cost-effectiveness studies determined their
own effectiveness data and provided one or more of a
selection of outcome measures, such as cost per case
averted, cost per death averted or cost per disability-
adjusted life year (DALY) averted. As in case of the outputs
reported, the selection of outcome measures varied
between studies, with most authors reporting results for
only one.
Sensitivity analysis
Cost estimates inevitably involve some assumptions and
methodological controversy. To account for this, careful
analysts need to identify critical assumptions and areas of
uncertainty and then re-estimate the results using differ-
ent assumptions to test the sensitivity of the results and
conclusions to such change. Of the studies reviewed,
approximately half provided some form of sensitivity
analysis. Eight (i.e. 73%) of the cost-effectiveness analysis
included this component, as opposed to four (29%) of
the studies that provided cost estimates.
Discussion
The present work adds to the literature on economic
aspects of the use of ITNs. A previous review covered the
costs and benefits provided in sixteen published and
unpublished studies from 13 countries [23]. It is assumed
that the "price of bednets" quoted in this earlier review
refers to the financial or economic cost per net delivered,
rather than the price nets were sold for in the market. Var-
iation in the quoted cost of mosquito nets ranged from
US$ 3.00 in China to US$ 72.00 in rural Cameroon, and
the cost for insecticide treatment from US$ 0.10 in China
to US$ 2.00 in urban Cameroon. The assumed and
observed life expectancy of nets varied from one to six
years [23].
More recent results are similar, though the sources of data
are different. Only four of the previously reviewed studies
were included in the present review, as they were pub-
lished in the English scientific literature. Here the cost per
net delivered ranged from US$ 0.58 for a public sector
programme in northern Vietnam to US$ 6.87 for a social-
marketing programme in four areas in Tanzania. Variation
in the cost of insecticide treatment was more pronounced.
A study from The Gambia reports cost per treatment to be
US$ 0.30, whereas delivery of treatment in remote areas of
Colombia was estimated at US$ 12.40. Unfortunately,
these costs could not be directly compared, because cost-
ing methodology varied too widely. The broad definition
of costing inevitably captured studies with methods that
would not fulfil economic standards of cost analysis.Malaria Journal 2006, 5:37 http://www.malariajournal.com/content/5/1/37
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Unexpectedly, however, even studies that claimed to be
costing or cost-effectiveness studies varied widely in qual-
ity.
A typology for ITN distribution and payment mechanisms
recently updated by J. Webster (pers. com.) was used to
categorize the studies included in this review. This indi-
cated that the largest number of cost estimates came from
programmes that use public distribution mechanisms and
provide nets free of charge. Correspondingly, this category
also held the largest variation in quality of the costing pre-
sented, ranging from very detailed estimates calculated as
a component of cost-effectiveness studies [e.g. [4]] to
"back of the envelope" figures used for advocacy [e.g.
[22]]. Costing of delivery strategies categorized as mixed
or private has not received much attention to date. Further
cost analyses and economic-evaluations of ITN pro-
grammes are thus necessary to close this gap and to pro-
vide much needed evidence as to which delivery and
payment methods, and combinations, present good value
for money and should be supported in order to achieve
targets outlined in the Roll Back Malaria Abuja targets [26]
and the Millennium Development Goals (http://
www.developmentgoals.org).
The present review also highlights the narrow perspective
frequently taken to arrive at cost estimates. Authors pre-
dominantly chose the provider perspective, failing to con-
sider the costs attributed to ITN users and society. This
lack of consideration is by no means limited to the costing
of ITN programmes, but has been reported for economic
evaluations of interventions to control communicable
and parasitic diseases [13,14]. However, user costs vary
depending on the degree to which strategies shift costs
from the provider to the user. For example, distribution
from a central location may be relatively cheap for the
programme but shifts costs to the users who need to travel
to acquire ITNs. Community-based distribution systems
will result in a different distribution of costs between the
provider and the user. With ITN programmes generally
aiming to reach certain target groups, such as the rural
poor (which tend to be at highest risk of deleterious
effects of malaria [e.g. [24,25]]), shifting of costs to the
users should not be overlooked.
A narrow perspective also pays insufficient attention to
the wastage of resources, such as leakage of nets and insec-
ticide to non-target groups. If nets or insecticide are taken
up by non-target groups, but still put to their intended
use, this could be considered as adequate use of the pro-
grammes resources, because it increases overall coverage.
However, if nets are used for other purposes, such as fish-
ing or bridal wear, and if insecticide is diverted to agricul-
tural use, then this should certainly be reflected in the ITN
delivery cost. Ideally, authors should document such
events, provide details on the type and scale of leakage,
and calculate cost estimates including and excluding it
[e.g. [19]].
This type of transparency should in fact be applied to all
aspects of the cost analysis, allowing the reader to judge
the reliability of the final cost estimate and, ideally, to
recalculate costs under different scenarios. Transparency
starts from a clear statement of the perspective taken and
should be followed through by citing the source of cost
data, listing the costs identified, the amounts required and
their value separately, rather than as composites and by
making assumptions explicit. By not adequately describ-
ing their methods of cost analysis, authors evoke the sus-
picion of omitting certain costs to advocate for a particular
intervention [13].
Only few costing studies on ITN interventions have inves-
tigated the potential cost implications of scaling-up.
Those studies that have investigated this issue have arrived
at different conclusions. For example, Aikins et al. [26]
noted a considerable difference in cost-effectiveness esti-
mate for two types of implementation in the Gambia.
When compared to a controlled intervention study, the
National Impregnated Bednet Programme had difficulties
controlling its field activities, which almost tripled the
cost per death averted (US$ 220 versus US$ 620). A recent
cost-effectiveness study on a nationwide ITN programme
in Malawi showed that as the programme expanded and
increased ITN sales over a 5-year period, costs per ITN dis-
tributed and per treated net year decreased from US$ 5.04
to US$ 1.92 and from US$ 7.69 to US$ 3.44, respectively
[27]. As highlighted by the authors, further economic
evaluations of other large-scale programmes using differ-
ent ITN delivery methods will be required to assess under
which conditions increasing returns to scale can be
expected in other contexts. In any case, extrapolation from
small-scale trials to the potential cost of an ITN interven-
tion at national or international scale [22] is unlikely to be
reliable, due to inevitable changes in returns to scale asso-
ciated with scaling-up [28]. Authors that wish to explore
the potential changes in cost when scaling-up an ITN
intervention should consider the use of non-linear cost
functions and other methods promoted by WHO-
CHOICE [29,30].
Costing of health interventions presents a challenge in the
selection of appropriate methods, but it is not too techni-
cal a task for non-economists. What investigators require
is a critical attitude towards their own work and an aspira-
tion to produce results that are meaningful in a specific
context and transferable to others. The following recom-
mendations are meant to help address some of the meth-
odological challenges specific to ITN distribution and to
make the process more accessible. Following the sugges-Malaria Journal 2006, 5:37 http://www.malariajournal.com/content/5/1/37
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tion of Gold et al. [18] a reference case scenario is pro-
vided, which aims at generating comparable results from
future studies.
Recommendations
Viewpoint
Cost analysis should be undertaken from the broadest
perspective, that of society, to incorporate all costs regard-
less of whom incurs them [18]. Other perspectives, such
as that of the provider, patient or Ministry of Health, can
be included alongside this perspective.
Costing
General costing methods are outlined elsewhere and
should be consulted prior to the study. To aid generalisa-
bility and to ensure transparency, the required resources,
their quantities and their value should be reported sepa-
rately. Specifics related to ITN programmes are as follows.
Resource identification
The costs of any activities undertaken to educate people to
facilitate behavioural change should be accounted for,
including any advertising that is part of the intervention.
It should also be made clear whether an intervention pro-
vides mosquito nets or treatment only, or whether it deliv-
ers both components. For the latter, separate costs should
be provided.
In areas where LLINs are being introduced alongside con-
ventional nets the resources associated with this change,
such as additional educational campaigns/materials and
the amount of insecticide wasted by re-treating LLINs dur-
ing net treatment campaigns should be included. For
example, the malaria control programme in Uganda treats
all nets while LLINs are being phased in. In 2004, an esti-
mated 25% of all nets were LLINs, amounting to approx-
imately 500,000 nets (A. Kilian, pers. com). In a recent
campaign in 20 districts the treatment of LLINs brought
for re-treatment resulted in a cost of approximately US$
100,000 (cost includes insecticide, equipment and imple-
mentation).
For intervention trials, sensitivity analysis should consider
the resources that may be required under routine pro-
gramme conditions. Research costs should not be
included in the intervention costs. However, it should be
investigated whether the programme would operate as
well if research were not carried out alongside it. If
research staff are considered to be essential for the inter-
vention, then this cost should be included [e.g. [5]].
Another parameter that should be subjected to sensitivity
analysis is the proportion of shared resources in cases
where distribution is carried out as a component of
another programme/campaign. Here it is particularly
important to be explicit about the criterion used to
attribute resource use (e.g. % time, % value of resources),
as the basis for the breakdown is always arguable. For col-
laboration between organisations (e.g. local NGO & inter-
national NGO), resources including overheads that are
relevant to the programme need to be identified. The final
cost estimate needs to reflect the fact that, for example, a
programme was made feasible because an international
NGO facilitated procurement, management, fund raising,
etc.
Programme management resources need to be identified
and clearly specified, even if the main purpose of the
study is to compare two interventions provided by the
same programme (e.g. ITN/IRS). To ensure generalisabil-
ity it needs to be clear what capacity is assumed to exist
and whether authors have calculated average costs for
delivery of each intervention or the incremental cost of
adding an intervention to an existing programme (e.g.
ITN delivery alongside vaccination campaigns). In areas
where a mix of locally made (cotton) and imported (pol-
yester, polyethylene) nets is being impregnated, the extra
resources required to treat the former need to be consid-
ered, as these nets take up at least twice the amount of
insecticide [e.g. [31]].
Resource measurement
An attempt should be made to measure and report the
leakage of resources, to be able to differentiate between
measured outputs (e.g. nets delivered) and outputs that
reach the intended target. To inform policy, it is essential
to determine the degree to which different approaches to
targeting achieve their aim and at what cost.
It should be established how long nets last under local
conditions. Observations to date indicate that assumed
life expectancies of more than three years are unrealistic
(except in the case of polyethylene nets such as Olyset®).
In general, a relevant timeframe needs to be used for the
costing. As most projects last for more than one year there
may be issues around price level adjustments, so that all
the costs can be expressed in the same year, and because
of lumped expenditure (i.e. high start-up costs, but falling
over time). The general recommendation with regards to
tracking of costs is to select a follow-up period that does
not bias the analysis in favour of one intervention over
another [17].
Resource valuation
Mosquito nets need to be treated as a capital item. Annu-
alization based on a 3 years life span is recommended.
Should surveys indicate otherwise, costs for observed and
assumed 3 year duration should be provided. To all capi-
tal items a discount rate of 3% should be applied, to be
consistent with the rate used by the World Bank [32]. Sen-
sitivity analysis should also include 0%, 5% and 10%, toMalaria Journal 2006, 5:37 http://www.malariajournal.com/content/5/1/37
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presents costs in their undiscounted form, as well as at
higher rates chosen by some analysts.
When comparing alternatives, for example ITNs and IRS,
the same or equivalent components for their delivery
need to be costed. When using cost estimates reported in
other studies, these need to have been presented transpar-
ently so that they can be adapted (e.g. by applying local
prices to standard quantities). Otherwise, costs for a spe-
cific study need to be identified, measured and valued and
to be assessed for consistency with other authors' esti-
mates. For programmes that recover costs through user
contributions, double counting needs to be avoided. For
the societal perspective these costs should be included,
whereas if the provider perspective is taken they should be
excluded [e.g. [5]].
Data analysis
To reflect the uncertainty in measurements, a sensitivity
analysis needs to be carried out on (at a minimum): dis-
count rate, frequency of net impregnation, procurement
cost of insecticide & net, number of people protected per
net, life span of net. Where it is necessary to estimate a
share of resources contributed from other programmes or
interventions, the assumptions used should be subjected
to sensitivity analysis.
Reporting of results
Cost estimates should be provided in US$ and local cur-
rency, and the year to which costs were adjusted needs to
be specified. Projects producing nets locally for sale need
to report on the cost of making/treating nets, not just the
price at which these were sold to users, which may not
fully measure the opportunity cost.
The cost per ITN delivered should be reported, as cost per
person sleeping under a net varies depending on cultural
practices and as cost per case of malaria prevented
depends on the incidence of malaria. Both are useful for
policy decisions in a given context, but the cost per net
delivered is best suited for comparing delivery strategies.
Cost-effectiveness studies should not just provide net
costs (i.e. subtracting resources saved from total imple-
mentation costs), as these cannot be compared to results
from costing studies.
Discussion of results
To put cost-estimates for a particular method, or combi-
nation of methods, into perspective, it is recommended
that they are compared to the per capita expenditure on
government health services in the country/region. This
does not improve on the comparability of costing studies
between countries, but will help readers to assess the
affordability of the intervention [e.g. [3]]. When reporting
results, one should beware of the assumptions required to
extrapolate these to calculate costs of scaling-up an inter-
Table 2: Recommendations for calculating and presenting cost results
Viewpoint Use societal perspective.
Sub-analyses can focus on specific perspectives such as provider, patient or Ministry of Health
Output Clarify whether intervention delivers nets or treatment or both
Calculate net and treatment costs separately
Resource identification Include all costs of behaviour change activities (including advertising)
Include any costs of treating LLINs in campaigns
Exclude research costs
Include relevant overheads of collaborating organizations (e.g. NGO contributions to procurement, management, etc)
Clarify what management capacity is assumed to exist and whether calculating average cost or incremental cost of adding 
intervention to an existing programme
Resource measurement Attempt to measure and report leakage of resources (e.g. nets used by individuals outside target groups)
Establish average lifespan of net under local conditions
Resource valuation Treat nets as a capital item.
Base case should assume life expectancy of 3 years and use discount rate of 3% Avoid double counting of user 
contributions where cost recovery applied, but ensure these are counted as user contributions when disaggregating 
costs by source
Sensitivity analysis Conduct sensitivity analysis on: discount rate (0%, 5%, 10% at a minimum); frequency of net impregnation, procurement 
cost of net and insecticide; number of people protected per net; lifespan of net Consider impact of research where this is 
conducted alongside a programme on programme effectiveness (see ref 5)
Vary proportion of shared resources where distribution carried out as part of another programme/campaign
Reporting of results Provide costs in US$ and local currency
Specify year in which costs calculated/adjusted
Report cost per ITN delivered and cost per person sleeping under a net
Discussion of results Compare costs with per capita government health expenditure to aid assessment of affordability
Be cautious in using cost estimates to scale up, and make explicit assumptions about whether marginal cost constant, 
increasing or decreasingMalaria Journal 2006, 5:37 http://www.malariajournal.com/content/5/1/37
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vention. To date, studies that have investigated the cost of
scaling-up health interventions are limited. Available data
indicate that scaling-up costs are highly specific to both
the type of intervention and its particular setting [30].
Without further study of potential additional cost and
without considering factors such as human resources,
geography and infrastructure, extrapolations are not valid
because they assume constant marginal costs.
The recommendations are summarized in Table 2
The reference case
To provide comparability between ITN costing studies it is
suggested that analysts include a reference case scenario. If
future costing studies adhere to this practice, it will finally
be feasible to compare the costs of different options for
ITN delivery. At the same time, authors maintain the free-
dom of analysing their data from other viewpoints that
may be more relevant to their specific context. Based on
the above recommendation the use of the following refer-
ence case scenario is proposed (Table 3).
Table 3: Reference case scenario
Parameter Suggested Reference Scenario Explanation
Perspective Societal To include all costs, not just those of the provider or 
patient.
Currency US$ A cost estimate in US$, indicating the year of conversion 
should be provided in addition to local currency
Life-span of mosquito net 3 years Assumptions have varied from 3 to 7 years, but field 
observations increasingly indicate a relatively short life 
span of polyester nets. Olyset® nets (made of 
polyethylene) are more durable and should be considered 
separately.
Re-treatment Annually Treatment of mosquito nets with modern pyrethroids is 
generally assumed to last 6 – 12 months. Evidence for 
LLINs (Olyset® and PermaNet®) indicates that treatment 
lasts for the life span of the net [7, 8]. While LLINs are 
phased in, they may be retreated alongside conventional 
nets. It should be investigated if this is the case.
Cost data Include:
All intervention costs (e.g. mosquito nets, insecticide, 
wages, transport, advertising, etc.)
All time cost, including care giving (formal/informal) and 
volunteers
Transportation and other non-medical services
Administrative costs for sick leave and for other transfers
Donated items
Costs for these and possible other ingredients (depending 
on programme specifics) should be collected. Costs can 
only be excluded once it has been established that they 
are insignificant in the context of the analysis [see 
reference 17 and 18 for further guidance). Quantities and 
prices need to be presented separately
Revenue Value and include From the societal perspective, funds from cost-recovery 
need to be included. This needs careful attention to avoid 
double counting. Clearly indicate cost-recovery when 
presenting results.
Adjustment of financial costs to calculated economic costs
Annualisation Life expectancy of capital items as specified above To obtain an equivalent annual cost for each capital outlay, 
an annuitization procedure needs to be followed. This 
requires an estimate of the life expectancy of each capital 
item and a decision on the discount rate to be used (see 
below).
Discount rate 3% Base-case calculations should use 3%, to be consistent 
with World Bank recommendations [32]. This should be 
varied in the sensitivity analysis, e.g. from 0 – 10%.
Reporting of results
Cost estimate Cost per net ITN delivered For programmes delivering untreated nets and insecticide 
treatment, the cost of both components should be quoted 
separately. Indicate whether the cost per ITN is the 
composite of the two costs or is achieved at lower/higher 
costMalaria Journal 2006, 5:37 http://www.malariajournal.com/content/5/1/37
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Conclusion
The cost of different ITN delivery strategies is important
when deciding which ones to scale-up, yet it is one of the
knowledge gaps remaining to be filled [10]. Many strate-
gies have not been costed at all and only some of the exist-
ing cost-estimates have been derived using appropriate
methods. Well-conducted studies have often used outputs
that are difficult to compare. A template for costing of ITN
interventions and reporting on results does not exist.
The limited role of health economics in generating essen-
tial evidence for scaling-up of ITNs cannot be explained
by the absence of general guidelines or other supporting
literature. More likely it partly results from the lack of ITN
specific recommendations, which has led to the observed
variation in methods and outputs, and partly from some
authors being reluctant to use any economic methods,
because these are misconceived as not applicable to
health care [33]. Until these obstacles are overcome, deci-
sion makers will lack important data to guide their efforts
of scaling-up coverage.
To advocate for the use of improved and standardised
methods, this review has drawn attention to the variations
in approaches taken to costing ITN programmes, and con-
sequently of study outputs, and the limitations of these.
This will hopefully allow ITN programme staff and their
donors to recognise the potential impact that costing of
their work could have, if results were readily comparable
to other studies and could be interpreted in other con-
texts. The suggested Reference Case scenario is meant to
further assist standardisation of new costing initiatives.
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